Status:
UNKNOWN
A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso
Lead Sponsor:
African Malaria Network Trust
Collaborating Sponsors:
London School of Hygiene and Tropical Medicine
Conditions:
Malaria
Eligibility:
All Genders
1-2 years
Phase:
PHASE1
Brief Summary
This will be a study of the safety of MSP 3 LSP candidate malaria vaccine in children aged 1-2 years in Burkina Faso. Three imminizations at 28 day intervals will be administratered subcuteneously on ...
Detailed Description
The study is a single centre randomized controlled and blinded study (observer blind). It will be conducted at the CNRFP Vaccinology unit located in Balonghin. Children in the catchments area within t...
Eligibility Criteria
Inclusion
- Children aged 1-2 years old
- Healthy by medical history and physical examination
- Signed Informed Consent by guardian/parent
- Resident in the study area village during the whole trial period
Exclusion
- Symptoms, physical signs of disease that could interfere with the interpretation of the trial results or compromising the health of the subjects
- Immunosuppressive therapy (steroids, immune modulators or immune suppressors) within 3 months prior recruitment. (for corticosteroids, this will mean prednisone, or equivalent,0.5 mg/kg/day. Inhaled and topical steroids are allowed.)
- Cannot be followed for any social, psychological or geographical reasons.
- Use of any investigational drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use up to 30 days after the third dose.
- Suspected or known hypersensitivity to any of the vaccine components or to previous vaccine.
- Laboratory abnormalities on screened blood samples out of range, more specifically refer to table 2.
- Planned administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of vaccine. An exception, is the receipt of an EPI or licensed vaccine (measles, oral polio, Hib, meningococcal and combined diphtheria, pertussis,tetanus vaccines) which may be given 14 days or more before or after vaccination
- Evidence of chronic or active hepatitis B infection
- Presence of chronic illness that, in the judgement of the investigator, would interfere with the study outcomes or pose a threat to the participant's health.
- Administration of immunoglobulin andor any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period
- History of surgical splenectomy.
- Moderate or severe malnutrition at screening defined as weight for age Z score less than 2
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2008
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00452088
Start Date
April 1 2007
End Date
May 1 2008
Last Update
May 7 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Projet de Développement de Vaccins Anti-Paludique- Centre National de Recherche et de Formation sur le Paludisme
Ouagadougou, Sapone, Burkina Faso